An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin

Urology

Volumn 47, Issue 6, 1996, Pages 840-844

  Gerber, Glenn S ^a,b   Kim, Jae H ^a   Contreras, Barbara A ^a   Steinberg, Gary D ^a   Rukstalis, Daniel B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG EFFECT; HUMAN; MALE; MICTURITION; PRIORITY JOURNAL; SCORING SYSTEM; URODYNAMICS;

EID: 0029889160     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00040-4     Document Type: Article

References (18)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. AHCPR Publication No. 94-0583. Rockville, Md, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. February, 1994.
2. Abrams P: In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 44: 153-155, 1994.
3. McConnell JD: Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 44: 156-158, 1994.
4. Bendix Holme J, Christensen MM, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, and Elkjaer Husted S: 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 28: 77-82, 1994.
5. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, and Dias N: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154: 105-109, 1995.
6. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, and Dias N: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 154: 110-115, 1995.
7. Abrams P. Objective evaluation of bladder outlet obstruction. Br J Urol (suppl.) 76: 11-15, 1995.
8. McConnell JD: Benign prostatic hyperplasia (editorial). J Urol 154: 402-403, 1995.
9. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 45: 406-413, 1995.
10. Gleason DM, and Bottaccini MR: Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn 13: 1-12, 1994.
11. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJG, and Abrams P: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50-56, 1994.
12. Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan M, and Milroy EJ: Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 60: 136-142, 1987.
13. Lim CS, and Abrams P: The Abrams-Griffiths nomogram. World J Urol 13: 34-39, 1995.
14. Lim CS, Reynard J, Cannon A, and Abrams PH: The Abrams-Griffiths number: a simple way to quantify bladder outlet obstruction. Neururol Urodyn 13: 475-476, 1994.
15. Rosier PF, de la Rosette JJ, Koldewijn EL, Debruyne FM, and Wijkstra H: Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol 153: 1520-1525, 1995.
16. Ko DS, Fenster HN, Chambers K, Sullivan LD, Jens M, and Goldenberg SL: The correlation of multichannel urodynamic pressure-flow studies and American Urological Association symptom index in the evaluation of benign prostatic hyperplasia. J Urol 154: 396-398, 1995.
17. Restorick JM, and Mundy AR. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol 63: 32-35 1989.
18. Chapple CR, Stott M, Abrams PH, Christmas TJ, and Milroy EJ: A 12-week placebo-controlled double-blind study of proazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 70: 285-294, 1992.